Table 6.
Log-rank tests of time to TKR among different HA cohorts.
Log-rank test | ||
---|---|---|
Index therapy | Chi-square | p value |
Euflexxa compared with Supartz/Hyalgan | 1.013 | 0.3142 |
Synvisc compared with Supartz/Hyalgan | 14.914 | 0.0001* |
Orthovisc compared with Supartz/Hyalgan | 2.274 | 0.1315 |
Statistically significant at alpha level of 0.05.